Staff Writer

OncLive®, the nation’s leading multimedia resource for oncology professionals and Pfizer (platinum sponsor) and Exelixis and Stemline (gold sponsors), are pleased to announce the inductees of the 11th Annual Giants of Cancer Care recognition program.

In an interview with OncLive, Jeffrey S. Weber, MD, PhD, from the Moffitt Cancer Center, University of South Florida, Tampa, explored the utilization of molecular and immune-targeted therapies as treatments for patients with advanced melanoma.

The explosive growth of mainstream social networking sites has encouraged the development of smaller, niche networks designed to connect patients who share a diagnosis; however, no one platform has established itself as a central health-networking hub.

The FDA has added text messaging to the ranks of e-mail digests, RSS feeds, podcasts, and Websites that comprise MedWatch, the agency's safety information and adverse event reporting program.

The Life Beyond Cancer Foundation, formerly known as the US Oncology Foundation, has launched its new Website.

Enacted in 1986, the Electronic Communications Privacy Act (ECPA) was designed to protect the electronic documents of private citizens from undue interference by law enforcement officials.

Provenge, an immunotherapy for patients with advanced prostate cancer, has become the first therapeutic vaccine for cancer ever approved by the FDA.

Interview about the IsoFlow infusion catheter

Three hot gadgets for Oncologists

June-December Calender

In the United States, more than 200,000 women receive a breast cancer diagnosis annually. Early detection offers patients the best chance for a cure, but may also lead to treatment dilemmas in some patients.

Notable sessions and events

Three hot Gadgets

Proton therapy centers are being built around the country, and one of the companies leading this effort is ProCure, a company dedicated to improving the lives of patients with cancer by increasing access to proton therapy. Since 2005, ProCure has developed several centers and more are underway.